Ascentage Pharma Group International (AAPG)
NASDAQ: AAPG · Real-Time Price · USD
31.73
-0.63 (-1.95%)
At close: Nov 7, 2025, 4:00 PM EST
32.00
+0.27 (0.85%)
After-hours: Nov 7, 2025, 4:47 PM EST
AAPG Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for AAPG stock has a target of 48, which predicts a 51.28% increase from the current stock price of 31.73.
Price Target: $48 (+51.28%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for AAPG stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|
| Strong Buy | 0 | 0 | 0 |
| Buy | 1 | 1 | 2 |
| Hold | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 |
| Total | 1 | 1 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Initiates $48 | Buy | Initiates | $48 | +51.28% | Nov 5, 2025 |
| JP Morgan | JP Morgan | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Mar 27, 2025 |
Financial Forecast
Revenue This Year
598.12M
from 980.65M
Decreased by -39.01%
Revenue Next Year
2.80B
from 598.12M
Increased by 368.64%
EPS This Year
-3.14
from -1.34
EPS Next Year
2.37
from -3.14
Financial currency is CNY. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 766.5M | 3.4B | |||
| Avg | 598.1M | 2.8B | |||
| Low | 499.2M | 1.8B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -21.8% | 473.3% | |||
| Avg | -39.0% | 368.6% | |||
| Low | -49.1% | 198.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -2.47 | 4.84 | |
| Avg | -3.14 | 2.37 | |
| Low | -3.68 | -0.80 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.